Los Angeles Capital Management LLC Acquires Shares of 20,986 G1 Therapeutics, Inc. (NASDAQ:GTHX)

Los Angeles Capital Management LLC bought a new stake in G1 Therapeutics, Inc. (NASDAQ:GTHX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 20,986 shares of the company’s stock, valued at approximately $48,000.

Other hedge funds have also made changes to their positions in the company. Rhumbline Advisers raised its stake in shares of G1 Therapeutics by 5,136.0% during the second quarter. Rhumbline Advisers now owns 50,632 shares of the company’s stock worth $115,000 after purchasing an additional 49,665 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of G1 Therapeutics in the 2nd quarter valued at approximately $404,000. Bank of New York Mellon Corp acquired a new stake in G1 Therapeutics in the second quarter valued at $304,000. SG Americas Securities LLC boosted its position in shares of G1 Therapeutics by 248.1% during the 2nd quarter. SG Americas Securities LLC now owns 47,124 shares of the company’s stock worth $107,000 after purchasing an additional 33,588 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in G1 Therapeutics by 20.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,858 shares of the company’s stock worth $1,632,000 after buying an additional 64,790 shares in the last quarter. Institutional investors and hedge funds own 24.21% of the company’s stock.

G1 Therapeutics Price Performance

G1 Therapeutics stock opened at $7.15 on Tuesday. The stock has a market capitalization of $378.16 million, a P/E ratio of -11.53 and a beta of 1.66. G1 Therapeutics, Inc. has a 12-month low of $1.08 and a 12-month high of $7.19. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 2.12. The firm’s 50-day moving average is $5.66 and its two-hundred day moving average is $4.39.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.07. G1 Therapeutics had a negative net margin of 76.93% and a negative return on equity of 136.98%. The firm had revenue of $16.55 million during the quarter, compared to analysts’ expectations of $15.88 million. Equities analysts predict that G1 Therapeutics, Inc. will post -0.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

GTHX has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of G1 Therapeutics in a report on Wednesday, August 7th. Wedbush downgraded G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright cut G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.